Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q1 2020 Xvivo Perfusion AB Earnings Call Transcript

Apr 09, 2020 / 09:30AM GMT
Release Date Price: kr124.31 (+12.59%)
Operator

Ladies and gentlemen, welcome to XVIVO Perfusion Report Webcast. I will now hand over to Magnus Nilsson, CEO. Please go ahead.

Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB

()-&

Welcome to this 30th quarterly report of XVIVO Perfusion, the interim report January to March 2020. And I have with me Christoffer Rosenblad, the CFO. Christoffer?

Christoffer Rosenblad;publ;CFO
Xvivo Perfusion AB;Deputy CEO, Deputy MD & Board Secretary

()- -

Hello.

Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB

()-&

Next slide, please. So first, the highlights of this very unusual Q1. We still have a strong cash position which is the primary message. So we have very limited cash consumption, cash consumption during Q1 in spite of a very heavy investment in R&D, as usual, and we end the quarter in a good financial position, SEK 159 million at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot